Gemtuzumab Ozogamicin Treatment Results in Decreased Proliferation and Differentiation of Human Megakaryocytes but Does Not Inhibit Mature Platelet Function

Mylotarg (Gemtuzumab ozogamicin [GO]), an antibody drug conjugate comprising a CD33-directed antibody linked to calicheamicin, is approved for use in certain acute myeloid leukemia patients. Following reports of prolonged thrombocytopenia and hemorrhagic events in a subset of patients, a detailed series of in vitro and ex vivo studies was performed at the request of regulators, both to look at the effects of GO on platelet production and to determine whether treatment with GO was likely to affect platelet aggregation under a variety of conditions. Treatment with GO resulted in cellular cytotoxicity and/or decreased differentiation during human megakaryocyte development. However, GO did not impair platelet aggregation under the experimental conditions evaluated. Ultimately, the effect of GO on megakaryocyte development observed in our studies was determined to have no impact on the risk-benefit assessment in the intended patient population, as thrombocytopenia is a known side effect of GO, and monitoring of platelet counts in patients is already strongly recommended.

[1]  C. Nielsen,et al.  Platelet function tests predict bleeding in patients with acute myeloid leukemia and thrombocytopenia , 2019, American journal of hematology.

[2]  Frederik Otzen Bagger,et al.  BloodSpot: a database of healthy and malignant haematopoiesis updated with purified and single cell mRNA sequencing profiles , 2018, Nucleic Acids Res..

[3]  L. Mecklenburg.  A Brief Introduction to Antibody–Drug Conjugates for Toxicologic Pathologists , 2018, Toxicologic pathology.

[4]  S. Meshinchi,et al.  Gemtuzumab ozogamicin for treatment of newly diagnosed CD33-positive acute myeloid leukemia. , 2018, Future oncology.

[5]  C. Morisco,et al.  Effects of Carvedilol Versus Metoprolol on Platelet Aggregation in Patients With Acute Coronary Syndrome: The PLATE-BLOCK Study. , 2018, The American journal of cardiology.

[6]  Jiang Liu,et al.  FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia , 2018, Clinical Cancer Research.

[7]  Jiunn H. Lin,et al.  Challenges of Antibody Drug Conjugates in Cancer Therapy: Current Understanding of Mechanisms and Future Strategies , 2018, Current Pharmacology Reports.

[8]  D. Stover,et al.  Inhibition of Megakaryocyte Differentiation by Antibody–Drug Conjugates (ADCs) is Mediated by Macropinocytosis: Implications for ADC-induced Thrombocytopenia , 2017, Molecular Cancer Therapeutics.

[9]  J. Kreeger,et al.  Liver Microvascular Injury and Thrombocytopenia of Antibody–Calicheamicin Conjugates in Cynomolgus Monkeys—Mechanism and Monitoring , 2016, Clinical Cancer Research.

[10]  Heather Donaghy,et al.  Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates , 2016, mAbs.

[11]  R. Dixit,et al.  Antibody Drug Conjugates: Nonclinical Safety Considerations , 2015, The AAPS Journal.

[12]  R. Abbate,et al.  Platelet function tests: a comparative review , 2015, Vascular health and risk management.

[13]  M. Sliwkowski,et al.  Potential Mechanisms for Thrombocytopenia Development with Trastuzumab Emtansine (T-DM1) , 2014, Clinical Cancer Research.

[14]  A. Attar.  Changes in the Cell Surface Markers During Normal Hematopoiesis: A Guide to Cell Isolation , 2014 .

[15]  M. Dittrich,et al.  Dabigatran, rivaroxaban, apixaban, argatroban and fondaparinux and their effects on coagulation POC and platelet function tests , 2014, Clinical chemistry and laboratory medicine.

[16]  M. Linden.  Using Platelet Function Testing to Guide Antiplatelet Therapy , 2013 .

[17]  R. Scharf.  Drugs that Affect Platelet Function , 2012, Seminars in Thrombosis & Hemostasis.

[18]  J. Italiano,et al.  High-content live-cell imaging assay used to establish mechanism of trastuzumab emtansine (T-DM1)--mediated inhibition of platelet production. , 2012, Blood.

[19]  K. Nelander,et al.  Ticagrelor inhibits human platelet aggregation via adenosine in addition to P2Y12 antagonism , 2012, Journal of thrombosis and haemostasis : JTH.

[20]  J. Bussel,et al.  Differences in platelet function in patients with acute myeloid leukemia and myelodysplasia compared to equally thrombocytopenic patients with immune thrombocytopenia , 2011, Journal of thrombosis and haemostasis : JTH.

[21]  A. Ricart.  Antibody-Drug Conjugates of Calicheamicin Derivative: Gemtuzumab Ozogamicin and Inotuzumab Ozogamicin , 2011, Clinical Cancer Research.

[22]  D Parent-Massin,et al.  Application of human CFU-Mk assay to predict potential thrombocytotoxicity of drugs. , 2009, Toxicology in vitro : an international journal published in association with BIBRA.

[23]  T. Lister,et al.  Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. , 2005, Blood.

[24]  I. Bernstein,et al.  Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33‐positive acute myeloid leukemia in first recurrence , 2005, Cancer.

[25]  M. Díaz-Ricart,et al.  Uremic platelet dysfunction: past and present. , 2005, Current hematology reports.

[26]  A. Leung,et al.  Thrombocytopenia after gemtuzumab is reversible by intravenous immunoglobulin , 2005, Leukemia.

[27]  M. Berger,et al.  Acute and long-term toxicities associated with gemtuzumab ozogamicin (Mylotarg) therapy of acute myeloid leukemia. , 2002, Clinical lymphoma.

[28]  K. Kottke-Marchant,et al.  The laboratory diagnosis of platelet disorders. , 2002, Archives of pathology & laboratory medicine.

[29]  A. Farrand,et al.  Plasma thrombopoietin levels in marrow transplant patients with veno-occlusive disease of the liver , 1998, Bone Marrow Transplantation.

[30]  M. Loudovaris,et al.  Immunocytochemistry and flow cytometry evaluation of human megakaryocytes in fresh samples and cultures of CD34+ cells. , 1996, Cytometry.

[31]  J. Sixma,et al.  Defects in platelet adhesion and aggregate formation in uremic bleeding disorder can be attributed to factors in plasma. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[32]  Guidelines on platelet function testing. The British Society for Haematology BCSH Haemostasis and Thrombosis Task Force. , 1988, Journal of clinical pathology.

[33]  I. Bernstein,et al.  Treatment of acute myeloid leukemia cells in vitro with a monoclonal antibody recognizing a myeloid differentiation antigen allows normal progenitor cells to be expressed. , 1987, The Journal of clinical investigation.

[34]  R. Branch,et al.  A clinical and experimental study of platelet function in chronic renal failure , 1972, Journal of clinical pathology.

[35]  H. Horowitz.  Uremic toxins and platelet function. , 1970, Archives of internal medicine.

[36]  M. Damelin.  Innovations for Next-Generation Antibody-Drug Conjugates , 2018, Cancer Drug Discovery and Development.

[37]  Hadi Falahatpisheh,et al.  Improving the Safety Profile of ADCs , 2018 .

[38]  M. Majekova,et al.  Carvedilol--a beta-blocker with considerable antiaggregatory effect on human blood platelets. , 2005, Bratislavske lekarske listy.

[39]  G. Escolar,et al.  Defective platelet adhesion on vessel subendothelium in uremic patients. , 1986, Blood.

[40]  P. Miescher,et al.  Drug-induced thrombocytopenia , 1980, Clinics in haematology.